
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Disco... Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company's lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT). Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.99 | 13.2067137809 | 22.64 | 25.7 | 21.0502 | 168436 | 23.19520878 | CS |
4 | -8.46 | -24.8166617776 | 34.09 | 36.11 | 21.0502 | 232013 | 26.82609041 | CS |
12 | -18.15 | -41.4572864322 | 43.78 | 61.07 | 15.3 | 344025 | 41.03047167 | CS |
26 | 7.96 | 45.0481041313 | 17.67 | 61.07 | 15.3 | 224573 | 39.64779372 | CS |
52 | 8.73 | 51.6568047337 | 16.9 | 61.07 | 15.0001 | 161789 | 38.36112112 | CS |
156 | 8.73 | 51.6568047337 | 16.9 | 61.07 | 15.0001 | 161789 | 38.36112112 | CS |
260 | 8.73 | 51.6568047337 | 16.9 | 61.07 | 15.0001 | 161789 | 38.36112112 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales